Joint associations of Interleukin-6 and apolipoprotein B with major adverse cardiovascular events in the UK biobank
Progress in Cardiovascular Diseases · 2026-08
DOI: 10.1016/j.pcad.2026.08.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Progress in Cardiovascular Diseases, 2026-08. Verfasst von Patrick Cheon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Wake Forest University School of Medicine, Winston-Salem, NC, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
AIMS: The relative contributions of inflammatory and atherogenic lipoprotein pathways to residual cardiovascular risk remain unclear. We examined the joint and independent associations of interleukin-6 (IL-6) and apolipoprotein B (ApoB) with major adverse cardiovascular events (MACE) and mortality. METHODS: Among 34,064 UK Biobank participants free of prevalent atherosclerotic cardiovascular disease with Olink proteomics, multivariable Cox models estimated hazard ratios (HRs) for MACE (myocardial infarction (MI), stroke, or cardiovascular death), MACE components, and all-cause mortality. Models adjusted for demographics, HDL cholesterol, triglycerides, lipid-lowering therapy, hypertension, diabetes, smoking, eGFR, BMI, and high sensitivity C-reactive protein. Participants were additionally classified into four groups by median IL-6 and an ApoB threshold of 90 mg/dL. RESULTS: Over a median 13.6 years, 2551 (7.5%) MACE events occurred. In continuous models, IL-6 and ApoB were each independently associated with MACE (IL-6 HR 1.11 per SD, 95% CI 1.07-1.16; ApoB HR 1.12 per SD, 95% CI 1.07-1.17), and a simultaneous 1-SD increase in both biomarkers conferred 22% higher MACE risk. Associations were endpoint-specific: ApoB was strongest for MI (HR 1.20, 1.14-1.27), IL-6 for cardiovascular death (HR 1.20, 1.12-1.29) and all-cause mortality (HR 1.17, 1.14-1.20). In categorical analyses, MACE risk rose stepwise relative to the Low IL-6, Low ApoB reference: HR 1.22 (95% CI 1.05-1.41) for high ApoB alone, 1.33 (95% CI 1.15-1.55) for high IL-6 alone, and 1.55 (95% CI 1.34-1.78) for both. CONCLUSION: IL-6 and ApoB were independently associated with cardiovascular events, with atherogenic lipoprotein burden predominating for MI and inflammatory signaling for cardiovascular and all-cause death.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wake Forest University School of Medicine, Winston-Salem, NC, USA.
- Department of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.
- Sports Cardiology Program, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
- Baylor Scott & White The Heart Hospital, Plano, TX, USA.
- Department of Cardiology, National University Heart Centre, Singapore.
- Inova Schar Heart and Vascular, Inova Health System, Fairfax, VA, USA.
Zitieren
APA
Cheon, P., McParland, J. T., Doherty, S., Rikhi, R. R., Petek, B. J., Khan, S., Chew, N., Sharma, G., Spitz, J., Kalra, D., & Shapiro, M. D. (2026). Joint associations of Interleukin-6 and apolipoprotein B with major adverse cardiovascular events in the UK biobank. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2026.08.008
Vancouver
Cheon P, McParland JT, Doherty S, Rikhi RR, Petek BJ, Khan S, et al. Joint associations of Interleukin-6 and apolipoprotein B with major adverse cardiovascular events in the UK biobank. Progress in Cardiovascular Diseases. 2026. doi:10.1016/j.pcad.2026.08.008
BibTeX
@article{Cheon2026,
author = {Cheon, Patrick and McParland, James T and Doherty, Sean and Rikhi, Rishi R and Petek, Bradley J and Khan, Shahzeb and Chew, Nicholas and Sharma, Garima and Spitz, Jared and Kalra, Dinesh and Shapiro, Michael D},
title = {Joint associations of Interleukin-6 and apolipoprotein B with major adverse cardiovascular events in the UK biobank},
journal = {Progress in Cardiovascular Diseases},
year = {2026},
doi = {10.1016/j.pcad.2026.08.008}
}
EUVIMED